New treatments for chronic urticaria
Kolkhir P. V., Altrichter S., Munoz M., Hawro T., Maurer M.
Annals of Allergy, Asthma and Immunology
Vol.124, Issue1, P. 2-12
Опубликовано: 2020
Тип ресурса: Обзор
DOI:10.1016/j.anai.2019.08.014
Аннотация:
Objective: Chronic urticaria (CU) is a common, heterogeneous, and debilitating disease. Antihistamines and omalizumab are the mainstay therapies of CU. Additional treatment options are needed. Here, we review the off and beyond label use of licensed drugs, novel treatments that are currently under development, and promising new targets. Data Sources: MEDLINE was searched for recent reports of the successful use of treatments in CU and promising targets for the development of novel treatment options. We also searched ClinicalTrials.gov for recent and ongoing randomized clinical trials in CU. Study Selections: Relevant articles were selected and reviewed. Results: Omalizumab, the treatment of choice in patients with antihistamine-resistant chronic spontaneous urticaria (CSU), should be explored for use in chronic inducible urticaria in children younger than 12 years with CSU and at higher doses. The off-label use of dupilumab, reslizumab, mepolizumab, and benralizumab can be effective in
Ключевые слова:
abatacept; adalimumab; ak 002; anakinra; azathioprine; azd 1981; benralizumab; Bruton tyrosine kinase inhibitor; canakinumab; cyclosporine; dupilumab; etanercept; fenebrutinib; gsk 2646264; immunoglobulin; infliximab; ligelizumab; lou 064; mepolizumab; methotrexate; monoclonal antibody; nadroparin; omalizumab; placebo; reslizumab; rilonacept; rituximab; tranexamic acid; ub 221; unclassified drug; unindexed drug; antiallergic agent; antihistaminic agent; benralizumab; dupilumab; ligelizumab; mepolizumab; omalizumab; reslizumab; UB-421; add on therapy; cholinergic urticaria; chronic urticaria; cold urticaria; dermographism; dose response; drug dose escalation; drug efficacy; drug response; drug safety; drug targeting; human; injection site reaction; loading drug dose; pathogenesis; priority journal; Review; solar urticaria; systematic review; child; chronic urticaria; immunology; off label drug use; pathology; Anti-Allergic Agents; Antibodies, Monoclonal, Humanized; Child; Chronic Urtica
Язык текста: Английский
ISSN: 1534-4436
Kolkhir P. V. Pavel Vladimirovich 1982-
Altrichter S.
Munoz M.
Hawro T.
Maurer M.
Колхир П. В. Павел Владимирович 1982-
Алтричтер С.
Муноз М.
Хаwро Т.
Маурер М.
New treatments for chronic urticaria
Текст визуальный непосредственный
Annals of Allergy, Asthma and Immunology
American College of Allergy, Asthma, & Immunology
Vol.124, Issue1 P. 2-12
2020
Обзор
abatacept adalimumab ak 002 anakinra azathioprine azd 1981 benralizumab Bruton tyrosine kinase inhibitor canakinumab cyclosporine dupilumab etanercept fenebrutinib gsk 2646264 immunoglobulin infliximab ligelizumab lou 064 mepolizumab methotrexate monoclonal antibody nadroparin omalizumab placebo reslizumab rilonacept rituximab tranexamic acid ub 221 unclassified drug unindexed drug antiallergic agent antihistaminic agent benralizumab dupilumab ligelizumab mepolizumab omalizumab reslizumab UB-421 add on therapy cholinergic urticaria chronic urticaria cold urticaria dermographism dose response drug dose escalation drug efficacy drug response drug safety drug targeting human injection site reaction loading drug dose pathogenesis priority journal Review solar urticaria systematic review child chronic urticaria immunology off label drug use pathology Anti-Allergic Agents Antibodies, Monoclonal, Humanized Child Chronic Urtica
Objective: Chronic urticaria (CU) is a common, heterogeneous, and debilitating disease. Antihistamines and omalizumab are the mainstay therapies of CU. Additional treatment options are needed. Here, we review the off and beyond label use of licensed drugs, novel treatments that are currently under development, and promising new targets. Data Sources: MEDLINE was searched for recent reports of the successful use of treatments in CU and promising targets for the development of novel treatment options. We also searched ClinicalTrials.gov for recent and ongoing randomized clinical trials in CU. Study Selections: Relevant articles were selected and reviewed. Results: Omalizumab, the treatment of choice in patients with antihistamine-resistant chronic spontaneous urticaria (CSU), should be explored for use in chronic inducible urticaria in children younger than 12 years with CSU and at higher doses. The off-label use of dupilumab, reslizumab, mepolizumab, and benralizumab can be effective in